Oral targeted therapies in the treatment of pulmonary arterial hypertension: A meta-analysis of clinical trials
Conclusions This meta-analysis suggests that all oral agents confer a therapeutic benefit. Of these, only PDE-5Is has a proven survival benefit. ERAs and riociguat are efficient in reducing clinical worsening, and ameliorating exercise capacity. Oral prostanoids have the significant adverse effects and weak therapeutic effects.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
More News: Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Hypertension | Respiratory Medicine | Sports Medicine | Study